We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-1.03%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$438M
AUM Growth
-$21.2M
Cap. Flow
+$25.3M
Cap. Flow %
5.78%
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11

Top Buys

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$17.2M
2
CYTK icon
Cytokinetics
CYTK
+$12M
3
CRGX
CARGO Therapeutics
CRGX
+$10.6M
4
JBIO
Jade Biosciences
JBIO
+$8.34M
5
ARVN icon
Arvinas
ARVN
+$7.17M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.83M
2
OCUL icon
Ocular Therapeutix
OCUL
+$8.31M
3
CMPX icon
Compass Therapeutics
CMPX
+$6.28M
4
CPRX
Catalyst Pharmaceutical
CPRX
+$5.67M
5
NYXH
Nyxoah
NYXH
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 98.24%
2 Miscellaneous 1.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$83.4M 19.04%
3,990,000
+69,400
+2% +$1.04M
TGTX icon
2
TG Therapeutics
TGTX
$8.53B
$40.6M 9.27%
2,280,000
– –
OCUL icon
3
Ocular Therapeutix
OCUL
$2.38B
$36.3M 8.29%
5,307,500
-1,345,638
-20% -$8.31M
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.75B
$21.1M 4.83%
515,000
– –
KROS icon
5
Keros Therapeutics
KROS
$223M
$16.8M 3.84%
367,500
– –
ARVN icon
6
Arvinas
ARVN
$604M
$14.8M 3.38%
555,000
+225,000
+68% +$7.17M
IMNM icon
7
Immunome
IMNM
$3.28B
$13.3M 3.05%
+1,102,500
New +$17.2M
CYTK icon
8
Cytokinetics
CYTK
$10.8B
$10.8M 2.46%
+198,500
New +$12M
CDXS icon
9
Codexis
CDXS
$182M
$10.7M 2.45%
3,455,000
+335,000
+11% +$1.08M
EWTX icon
10
Edgewise Therapeutics
EWTX
$4.8B
$10.4M 2.39%
580,000
-85,000
-13% -$1.48M
CPRX
11
DELISTED
Catalyst Pharmaceutical
CPRX
$9.91M 2.27%
640,000
-364,355
-36% -$5.67M
CRGX
12
DELISTED
CARGO Therapeutics
CRGX
$9.12M 2.08%
+555,700
New +$10.6M
JSPR icon
13
Jasper Therapeutics
JSPR
$23.3M
$8.9M 2.03%
392,000
-43,573
-10% -$1.05M
NRIX icon
14
Nurix Therapeutics
NRIX
$2.79B
$8.74M 2%
418,928
+151,718
+57% +$2.36M
TRVI icon
15
Trevi Therapeutics
TRVI
$2.56B
$7.88M 1.8%
2,645,000
– –
ETON icon
16
Eton Pharmaceutcials
ETON
$1.79B
$7.88M 1.8%
2,395,000
-50,781
-2% -$178K
APLT
17
DELISTED
Applied Therapeutics
APLT
$7.85M 1.79%
1,680,000
-90,000
-5% -$426K
FDMT icon
18
4D Molecular Therapeutics
FDMT
$824M
$7.26M 1.66%
345,750
+1,627
+0.5% +$40.8K
IOVA icon
19
Iovance Biotherapeutics
IOVA
$3.74B
$7.19M 1.64%
897,000
– –
SLRN
20
DELISTED
ACELYRIN
SLRN
$6.97M 1.59%
1,580,000
– –
URGN icon
21
UroGen Pharma
URGN
$2.22B
$6.91M 1.58%
412,000
+142,000
+53% +$2.02M
PCVX icon
22
Vaxcyte
PCVX
$9.1B
$6.42M 1.47%
85,000
– –
BDSX icon
23
Biodesix
BDSX
$300M
$6.15M 1.41%
201,000
+174,267
+652% +$4.98M
NAMS icon
24
NewAmsterdam Pharma
NAMS
$3.2B
$6.05M 1.38%
315,000
-388
-0.1% -$7.78K
XOMA
25
DELISTED
Xoma
XOMA
$5.92M 1.35%
250,000
– –
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2024 Portfolio in Review

As of Q2 2024, Opaleye Management held 62 positions worth $438M, down 4.6% from $459M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Opaleye Management deployed $25.3M of net new capital in Q2 2024, opening 9 new positions and adding to 15 existing holdings. Its largest new stake was Immunome: 1,102,500 shares worth $13.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ocular Therapeutix, an estimated $8.31M trimmed.

  • Opaleye Management's largest Q2 2024 buy was Immunome: 1,102,500 shares worth $13.3M.
  • Opaleye Management added most to Arvinas in Q2 2024, an estimated $7.17M increase.
  • Opaleye Management's biggest Q2 2024 reduction was Ocular Therapeutix, cutting an estimated $8.31M.
  • Opaleye Management fully exited Crinetics Pharmaceuticals in Q2 2024, selling an estimated $9.83M.
  • Opaleye Management's ten largest holdings make up 59% of its $438M portfolio in Q2 2024.
  • Opaleye Management opened 9 new positions and closed 11 in Q2 2024.
  • Opaleye Management's portfolio value fell 4.6% quarter-over-quarter to $438M.

Based on Opaleye Management's 13F filing for Q2 2024, filed 14 Aug 2024.